NasdaqCM - Delayed Quote USD

Verastem, Inc. (VSTM)

9.38 +0.16 (+1.79%)
At close: April 26 at 4:00 PM EDT
9.65 +0.27 (+2.88%)
After hours: April 26 at 7:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for VSTM

Recent News: VSTM

View More
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer

Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Business Wire 9 days ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire 23 days ago
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
Business Wire last month
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
Business Wire last month
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs

Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
Business Wire last month
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Business Wire last month
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
Business Wire last month
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc

Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
GuruFocus.com 2 months ago
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)

Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
GuruFocus.com 2 months ago
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024

3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
InvestorPlace 2 months ago
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
Business Wire 2 months ago
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy

Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Zacks 3 months ago
View More

Related Tickers

ENTA Enanta Pharmaceuticals, Inc.
12.37
-0.88%
 
GLYC GlycoMimetics, Inc.
1.6400
-4.09%
 
RIGL Rigel Pharmaceuticals, Inc.
1.1000
0.00%
 
IGMS IGM Biosciences, Inc.
9.40
+22.88%
 
KRYS Krystal Biotech, Inc.
156.88
+0.77%
 
MGNX MacroGenics, Inc.
14.56
+1.32%
 
PHAT Phathom Pharmaceuticals, Inc.
9.18
+0.88%
 
ONCT Oncternal Therapeutics, Inc.
8.29
+0.97%
 
IDYA IDEAYA Biosciences, Inc.
39.94
+3.42%
 
MOR MorphoSys AG
18.04
-0.50%